1X10^6 human PBMCs were surface stained with 5 ul FITC Plus Anti-Human CD3 (FITC-65133, Clone:OKT3), or Mouse IgG2a Isotype Control. Cells were not fixed. Lymphocytes were gated.

1X10^6 human PBMCs were surface stained with 5 ul FITC Plus Anti-Human CD3 (FITC-65133, Clone:OKT3), or Mouse IgG2a Isotype Control. Cells were not fixed. Lymphocytes were gated.

1X10^6 human PBMCs were surface stained with 5 ul PE Anti-Human CD3 (PE-65133, Clone:OKT3), or Mouse IgG2a Isotype Control. Cells were not fixed. Lymphocytes were gated.

1X10^6 human PBMCs were surface stained with 5 ul PE Anti-Human CD3 (PE-65133, Clone: OKT3), or Mouse IgG2a Isotype Control. Cells were not fixed. Lymphocytes were gated.

1X10^6 human PBMCs were surface co-stained with FITC Anti-human CD19 and 0.2 ug Anti-Human CD3 (65133-1-Ig, Clone: OKT3) labeled with FlexAble CoraLite® Plus 647 Antibody Labeling Kit for Mouse IgG2a (KFA043) or CoraLite® Plus 647 conjugated Mouse IgG2a Isotype Control. Cells were not fixed. Lymphocytes were gated.

1X10^6 human PBMCs were surface stained with 0.2 ug Anti-Human CD3 (65133-1-Ig, Clone: OKT3) labeled with FlexAble CoraLite® Plus 647 Antibody Labeling Kit for Mouse IgG2a (KFA043) (red) or CoraLite® Plus 647 conjugated Mouse IgG2a Isotype Control. Cells were not fixed. Lymphocytes were gated.

1X10^6 human PBMCs were surface co-stained with CL488 Anti-Human CD19 and 5 ul APC Anti-Human CD3 (APC-65133, Clone: OKT3) or Mouse IgG2a Isotype Control. Cells were not fixed. Lymphocytes were gated.

1X10^6 human PBMCs were surface stained with 5 ul APC Anti-Human CD3 (APC-65133, Clone: OKT3) or Mouse IgG2a Isotype Control. Cells were not fixed. Lymphocytes were gated.

1X10^6 human PBMCs were surface stained with 5 ul Atlantic Blue™ Anti-Human CD3 (AB-65133, Clone:OKT3) or Mouse IgG2a Isotype Control. Cells were not fixed. Lymphocytes were gated.

1X10^6 human PBMCs were surface stained with 5 ul Atlantic Blue™ Anti-Human CD3 (AB-65133, Clone:OKT3) or Mouse IgG2a Isotype Control. Cells were not fixed. Lymphocytes were gated.

1X10^6 human PBMCs were surface co-stained with FITC Anti-Human CD19 and 5 ul Cardinal Red™ Anti-Human CD3 (CR-65133, Clone:OKT3) or Mouse IgG2a Isotype Control. Cells were not fixed. Lymphocytes were gated.

1X10^6 human PBMCs were surface stained with 5 ul Cardinal Red™ Anti-Human CD3 (CR-65133, Clone:OKT3) (red) or Mouse IgG2a Isotype Control. Cells were not fixed. Lymphocytes were gated.

1X10^6 human PBMCs were surface co-stained with FITC Anti-Human CD19 and 5 ul CoraLite® Plus 405 Anti-Human CD3 (CL405-65133, Clone:OKT3) or Mouse IgG2a Isotype Control. Cells were not fixed. Lymphocytes were gated.

1X10^6 human PBMCs were surface stained with 5 ul CoraLite® Plus 405 Anti-Human CD3 (CL405-65133, Clone:OKT3) (red) or Mouse IgG2a Isotype Control. Cells were not fixed. Lymphocytes were gated.

1X10^6 human peripheral blood lymphocytes were surface stained with APC-Anti-Human CD19 (APC-65145, Clone: SJ25C1) and 5.00 ul CoraLite® Plus 488-conjugated Anti-Human CD3 (CL488-65133, Clone: OKT3). Cells were not fixed.

1X10^6 human peripheral blood lymphocytes were surface stained with APC-Anti-Human CD19 (APC-65145, Clone: SJ25C1) and CoraLite® Plus 488-conjugated Mouse IgG2a isotype control antibody. Cells were not fixed.